CTMX CytomX Therapeutics Inc
Price (delayed)
$0.6087
Market cap
$48.76M
P/E Ratio
1.6
Dividend/share
N/A
EPS
$0.38
Enterprise value
$19.06M
CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. CytomX is developing a novel class of investigational conditionally activated antibody therapeutics,
Highlights
CytomX Therapeutics's net income has surged by 130% QoQ
The EPS has soared by 124% from the previous quarter
Key stats
What are the main financial stats of CTMX
Market
Valuations
Earnings
Shares outstanding
80.1M
Market cap
$48.76M
Enterprise value
$19.06M
Price to earnings (P/E)
1.6
Price to book (P/B)
N/A
Price to sales (P/S)
0.37
EV/EBIT
0.59
EV/EBITDA
0.5
EV/Sales
0.14
Revenue
$138.1M
Gross profit
$138.1M
Operating income
$25M
Net income
$31.87M
EBIT
$32.09M
EBITDA
$37.95M
Free cash flow
-$86.54M
Per share
Balance sheet
Liquidity
EPS
$0.38
EPS diluted
$0.38
Free cash flow per share
-$1.02
Book value per share
-$0.01
Revenue per share
$1.64
TBVPS
$1.41
Total assets
$120.53M
Total liabilities
$120.99M
Debt
$9.39M
Equity
-$456,000
Working capital
$21.53M
Debt to equity
-20.58
Current ratio
1.25
Quick ratio
1.22
Net debt/EBITDA
-0.78
Margins
Efficiency
Dividend
EBITDA margin
27.5%
Gross margin
100%
Net margin
23.1%
Operating margin
18.1%
Return on assets
21.1%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
92.3%
Return on sales
23.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CTMX stock price
How has the CytomX Therapeutics stock price performed over time
Intraday
4.95%
1 week
2.46%
1 month
-10.12%
1 year
-71.56%
YTD
-40.9%
QTD
-4.26%
Financial performance
How have CytomX Therapeutics's revenue and profit performed over time
Revenue
$138.1M
Gross profit
$138.1M
Operating income
$25M
Net income
$31.87M
Gross margin
100%
Net margin
23.1%
CytomX Therapeutics's net income has surged by 130% QoQ
CTMX's net margin has surged by 112% since the previous quarter
The gross profit is up by 36% year-on-year and by 9% since the previous quarter
CTMX's revenue is up by 36% year-on-year and by 9% since the previous quarter
Growth
What is CytomX Therapeutics's growth rate over time
Valuation
What is CytomX Therapeutics stock price valuation
P/E
1.6
P/B
N/A
P/S
0.37
EV/EBIT
0.59
EV/EBITDA
0.5
EV/Sales
0.14
The EPS has soared by 124% from the previous quarter
CTMX's P/E is 79% lower than its last 4 quarters average of 7.3
CTMX's equity has surged by 99% year-on-year and by 98% since the previous quarter
The stock's P/S is 92% less than its 5-year quarterly average of 4.5 and 61% less than its last 4 quarters average of 0.9
CTMX's revenue is up by 36% year-on-year and by 9% since the previous quarter
Efficiency
How efficient is CytomX Therapeutics business performance
CTMX's return on assets has surged by 160% since the previous quarter
The ROS has soared by 95% from the previous quarter
Dividends
What is CTMX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CTMX.
Financial health
How did CytomX Therapeutics financials performed over time
The company's total liabilities has shrunk by 51% YoY and by 26% QoQ
CTMX's total assets is down by 40% YoY and by 13% from the previous quarter
CTMX's equity has surged by 99% year-on-year and by 98% since the previous quarter
CTMX's debt is down by 33% year-on-year and by 11% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.